On December 15, 2005, the FDA re-issued a Final Rule & Order on the license status of the anthrax vaccine [REF].
In December 2008, the FDA approved the new BioThrax IM formulation for intramuscular injections thus reducing the immunization schedule from a total of 6 shots to 5 shots (see below).